FPT
8.4.2022 11:49:11 CEST | Business Wire | Press release
In the Annual General Meeting 2022 (AGM 2022), FPT Corporation (FPT) has announced its goal to be among the Top 50 global end-to-end digital transformation service providers by 2030 and plans to continue working toward the long-term goal of becoming a standard-bearing digital enterprise.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220408005158/en/
Last year marked FPT’s effort to “rebirth” as the number of projects worth over 5 million USD increased by 111%. The firm’s global revenue in 2021 reached 1.6 billion USD, which grew nearly 20% year on. Foreign markets also recorded positive growth, including the Americas (+52%) and APAC (+27%).
FPT has pledged to become a strategic partner for businesses worldwide. In the 2022 - 2024 period, FPT shall continue to pursue this orientation, with the core mission of “Promoting rapid growth, developing new technology products, and providing digital transformation services on a large scale”, as mentioned by FPT Chairman Truong Gia Binh in FPT’s 2021 Annual Report.
To achieve this mission, Vietnam’s largest IT services provider plans to continue projecting on a balanced basis in three core pillars: Business – Governance – Technology. As Dr. Binh emphasized during the meeting, it is the firm’s strategy to provide comprehensive solutions to meet global businesses and each individual’s most basic demands.
With customers varying from large private enterprises, SMEs to individuals, FPT thrives on accommodating each group with unique services, combining different technologies to enhance business management, administration, and most importantly, customer services at every touchpoint. This highlights the firm’s growth strategy based on data-driven operations, a customer-centric motto, and breakthrough technology solutions.
According to FPT CEO Nguyen Van Khoa, technology-wise, the firm will leverage on-trend technologies to provide world-class digital transformation solutions and realize breakthrough opportunities for its shareholders.
As Vietnam’s technology pioneer, FPT plans to invest heavily in core technologies such as AI, Cloud, Big Data, Blockchain, and Hyper Automation. The Made-by-FPT ecosystem is also targeted as FPT's key growth driver in the long term, with a revenue growth rate of 42.8% in 2021.
FPT sets its message for 2022 to be: “Determined to fight” and plans to innovate in business and sales activities, expand its customer base in all sizes and fields globally. Promoting a long-term sustainable growth strategy, the firm targets a 19% growth in revenue and 20.2% in profit before tax for the following year.
About FPT Corporation
FPT Corporation is a globally leading technology and IT services provider headquartered in Vietnam, with nearly US$1.6 billion in revenue and 37,000 employees. As a pioneer in digital transformation, FPT delivers world-class services in Smart factories, Digital platforms, RPA, AI, IoT, Enterprise Mobility, Cloud, AR/VR, Business Applications, Application Services, BPO, and so on. The company has served over 1000+ customers worldwide, 85 of which are Fortune Global 500 companies in Aerospace & Aviation, Automotive, Banking and Finance, Logistics & Transportation, Utilities, and more. For more information, please visit www.fpt-software.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005158/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom